Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cofsils is a prominent consumer healthcare brand developed by Cipla Health, specializing in over-the-counter (OTC) treatments for sore throat and cough. The brand's most recognized product is the Cofsils Lozenge, which typically contains a combination of two antiseptic agents: 2,4-dichlorobenzyl alcohol and amylmetacresol. These components provide rapid relief by targeting bacteria and viruses in the oral cavity and throat, while also exerting a mild local anesthetic effect. Beyond lozenges, the Cofsils portfolio includes specialized cough syrups such as Cofsils DX (containing dextromethorphan and chlorpheniramine for dry cough) and Cofsils Wet Cough (containing expectorants and bronchodilators), as well as Cofsils Gargle (povidone-iodine) and Cofsils Naturals (herbal ingredients). It is widely distributed in the Indian market for the symptomatic management of upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cofsils.